An Open-label, Crossover Study to Compare Different Formulations and to Evaluate Effect of Food on Pharmacokinetics of TAS-116 in Patients with Advanced Solid Tumors
Latest Information Update: 15 Sep 2022
Price :
$35 *
At a glance
- Drugs Pimitespib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 06 Aug 2022 Status changed from not yet recruiting to completed as per results published in the Investigational New Drugs
- 06 Aug 2022 Results published in the Investigational New Drugs
- 14 Nov 2018 New trial record